Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Eur J Med Chem. 2019 Jul 1;173:282-293. doi: 10.1016/j.ejmech.2019.04.022. Epub 2019 Apr 16.
Two series of andrographolide derivatives with introduction of amide moiety into ring A by Beckmann rearrangement were synthesized. In series 1, the ring A was converted to caprolactam, and an amide moiety was linked to C-19 of ring A in series 2. Among them, compound 8h exhibited obvious inhibition on HK2 enzyme activity (IC = 9.36 ± 0.08 μM) and LPS-induced NO production in RAW264.7 cells (IC = 22.38 ± 3.57 μM), and potent binding affinity with HK2 (Kd = 5.12 ± 0.82 μM). The preliminary structure-activity relationships (SARs) suggested that the formation of caprolactam of ring A and esterification of C-19-hydroxyl could improve the inhibitory effects on HK2 enzyme of andrographolide derivatives. Furthermore, compound 8h significantly reduced the levels of IL-1β and IL-6, down-regulated the expressions of iNOS and COX-2. Its anti-inflammatory effect was related to the inhibition of both NF-κB pathway and glycolysis enzyme HK2. Since HK2 could be a novel and effective target for anti-inflammation, compound 8h might be a new anti-inflammatory agent targeting at HK2, or serve as a lead compound to design and synthesize more HK2 inhibitors with better inflammatory effects.
通过贝克曼重排将酰胺部分引入环 A 中,合成了两个系列的穿心莲内酯衍生物。在系列 1 中,环 A 被转化为己内酰胺,在系列 2 中环 A 的 C-19 连接有酰胺部分。其中,化合物 8h 对 HK2 酶活性(IC = 9.36 ± 0.08 μM)和 LPS 诱导的 RAW264.7 细胞中 NO 产生具有明显的抑制作用(IC = 22.38 ± 3.57 μM),并且与 HK2 具有很强的结合亲和力(Kd = 5.12 ± 0.82 μM)。初步的构效关系(SAR)表明,环 A 中环的己内酰胺的形成和 C-19-羟基的酯化可以提高穿心莲内酯衍生物对 HK2 酶的抑制作用。此外,化合物 8h 显著降低了 IL-1β 和 IL-6 的水平,下调了 iNOS 和 COX-2 的表达。其抗炎作用与 NF-κB 通路和糖酵解酶 HK2 的抑制有关。由于 HK2 可能是一种新型有效的抗炎靶点,化合物 8h 可能是一种针对 HK2 的新型抗炎药物,或者作为一个先导化合物,设计和合成具有更好抗炎效果的更多 HK2 抑制剂。